Navigation Links
STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
Date:11/2/2009

ally products such as the ICL used in non-reimbursed elective procedures, the challenge of managing our foreign subsidiaries, the risk that sales of our newly introduced products may not restore profitability to our U.S. IOL product line, our ability to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance and to demonstrate to the agency that its past concerns have been resolved, the willingness of surgeons and patients to adopt a new product and procedure, and the potential effect of recent negative publicity about LASIK on the demand for refractive surgery in general in the U.S. STAAR assumes no obligation to update its forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

STAAR's current data on the accommodating properties of the Collamer material derive from the reports of individual independent clinicians and have not been subjected to large scale clinical studies. STAAR's current nanoFLEX IOL does not currently have an FDA labeling claim for accommodation. STAAR cannot assure that its further research will support a claim that either its current Collamer lenses or future designs restore the eye's ability to accommodate. If clinical research does not support these claims, or supports only a narrow range of accommodation, STAAR's Collamer accommodation project may not result in increased sales. New lens designs may require clinical research studies and applying for the FDA's premarket approval, which are expensive and could result in delay or denial of approval.

Use of Non-GAAP Information

This news release presents selected items from the Company's Condensed Consolidated Statements of Operations as reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and also on a non-GAAP basis after excluding certain non-recurring expenses, and excluding changes in currency. None of the
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 Instacare Corp. (OTC Bulletin Board: ... life-enhancing prescription drugs and diagnostics and at home ... leading developer and provider of e-health technologies and ... today that as part of the preparation of ... to add two new Directors and has rejected, ...
(Date:12/17/2009)... -- Express Scripts, Inc. (Nasdaq: ESRX ... management companies in North America, announced today ... association of seizure risk among epilepsy patients ... The study found no evidence that switching ... generic substitution, was associated with increased emergency ...
(Date:12/17/2009)... BioTherapeutics, Inc. (NYSE-Amex: PLX ) today announced ... Sales and Commercial Affairs. In this newly ... responsible for all commercial activities, including pre-launch and ... the collaboration agreement between the Company and Pfizer ... emerge from the Company,s pipeline. Ms. Lauterbach ...
Breaking Medicine Technology:Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 2Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 4Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 1Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 2Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 3Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 1Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 2Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 1Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 2
... Abeome Corporation, a,Georgia-based biotech company, announced today ... a collaboration with Cato Research Ltd.,its global ... collaboration will help support continued development of ... technology vastly improves the development of,monoclonal antibodies ...
... as the Clinical Gold Standard ... from Decision Resources, WALTHAM, Mass., July 15 ... and advisory firms focusing on pharmaceutical and,healthcare issues, ... of depressive mood episodes in patients who suffer ...
Other Medicine Technology:Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2
(Date:12/17/2009)... Dec. 17 The Department of Justice ... state of New York have entered into settlement ... allegations that they submitted false claims to the ... The New York Medicaid program provides coverage for ... valid certificates showing that they received proper training. ...
(Date:12/17/2009)... Life" in Majority Leader,s Revisions to Senate Health ... 17 Americans United for Life Action ... to Senate Majority Leader Harry Reid as he ... revisions to a bill - to the Senate ... to include "specific language that ensures your legislation ...
(Date:12/17/2009)... ,Hopenhagen, the city is calling itself, ... international conference on climate change. Narconon has its ... of the worldwide Narconon drug education ... from climate change. But the streets thrum with ... by with flashing blue lights - a youth ...
(Date:12/17/2009)... not be beneficial , , THURSDAY, Dec. 17 (HealthDay News) ... the immediate effect of the fish oil fatty acids ... increase in blood fats and the molecules that help ... that the acute response has some potentially negative effects ... long-term intake," said Lindsay E. Robinson, an associate professor ...
(Date:12/17/2009)... fall down on prevention, experts say , , THURSDAY, ... surgeons are getting better at treating heart attacks ... ignoring the basic rules for preventing them, according ... , Topping the list: too little exercise, too ... adults surveyed last year reported no activity vigorous ...
Breaking Medicine News(10 mins):Health News:Three New York City Home Health Agencies Pay $9.7 Million to the United States to Settle False Claims Act Claims 2Health News:Pro-Life Leader Sends Urgent Letter to Senator Reid 2Health News:Save the Planet. Stop Smoking Dope, Says Narconon 2Health News:Could Omega-3s Boost Blood Fat Levels? 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 3
... support program with the goal to help healthcare professionals optimize outcomes ... ... (PRWEB) January 29, 2009 -- Though rare, gastrointestinal stromal tumors (GISTs) ... with an estimated 3,300 to 6,000 new cases reported each year ...
... message during the big gameMINNEAPOLIS, Jan. 29 The ... ads as it is for the actual football game. ... from ClearWay Minnesota that somberly reminds Minnesotans that "we ... and health consequences of tobacco use are explored though ...
... Researchers from Boston University School of Medicine (BUSM) and ... have found that children born more than three months premature, ... the modified checklist for autism in toddlers (M-CHAT). Children ... for developing autism. These findings appear in the January ...
... A new way of making LEDs could see household ... years. , Gallium Nitride (GaN), a man-made semiconductor ... light but uses very little electricity. Until now high ... wide spread use in homes and offices. , ...
... years; lawmakers demand criminal probe after U.S. health officials ... 2007 and 2008. , , WEDNESDAY, Jan. 28 (HealthDay News) ... late Wednesday for all peanut products made over the ... the current salmonella outbreak. , The recall was initiated ...
... Jan. 28 Consumer Watchdog warned that the move by ... California will lead to degradation of the quality of patient ... the interest of nursing home owners over patients.The current agreements ... protect the right of caregivers to blow the whistle on ...
Other Medicine News:Health News:Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 2Health News:Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 3Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 2Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 3Health News:Study finds preemies more likely to score positive 2Health News:Low-cost LEDs to slash household electric bills 2Health News:All Products at Georgia Peanut Plant Recalled 2Health News:All Products at Georgia Peanut Plant Recalled 3Health News:All Products at Georgia Peanut Plant Recalled 4
Inquire...
... Array Multifocal IOL was designed to provide ... from glasses in most situations. While distance ... similar to that of a single vision ... better and about 19 in 20 people ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Zeus Scientific, Inc. ... for the qualitative and quantitative ... human serum by the indirect ... assay can determine or confirm ...
Medicine Products: